

#

**Study #NNMC-60: A Phase I Trial of Etoposide and Cisplatin Plus Chest Radiotherapy for Patients with Limited Stage Small Cell Lung Cancer**

**Location:** NNMC, Bethesda

NAV1.954722.001

**Date:** December, 1993 - Present

**Primary**

**Researchers:** CAPT J. Phares, MC USN and Dr. Bruce E. Johnson, M. D.

**Sponsors:** Clinical Investigation Program, NNMC

**Human**

**Subjects:** Number unknown. Patients with histologically confirmed diagnosis of SCLS and no previous chemotherapy or thoracic/cranial radiotherapy. Informed consent obtained in writing.

**Purpose: Protocol: B93-082**

1. To determine the maximum tolerated dose of cisplatin and a 12-21 day course of oral etoposide with 45 Gy of BID concurrent chest radiotherapy.
2. To determine the maximum tolerated dose of chest radiotherapy administered with the maximum tolerated dose of etoposide cisplatin for patients with limited stage small cell lung cancer.

**Category:** Treatment use of Radiation

**Records:** NNMC, Bethesda

**Classification:** Unclassified

CIP - NNMC - ENCL (26)